HEM Pharma (CEO Joseph), a microbiome healthcare company, announced on the 15th that it has published its report for the third quarter of 2024.
Sales in the third quarter of this year amounted to KRW 3.2 billion, a 300.5% increase from the same period last year, and continued to rise steadily, growing by 9.8% from sales of KRW 2.9 billion in the previous second quarter. Cumulative sales in the third quarter of 2024 are KRW 8.7 billion, which significantly exceeds annual sales of KRW 3.7 billion in 2022 and is a 63.7% increase compared to annual sales of KRW 5.3 billion in 2023. This year’s expected annual sales are expected to exceed twice that of the previous year.
HEM Pharma is also showing improvement in profit and loss. The cumulative operating profit ratio in the third quarter of this year improved by 247.2% points compared to the cumulative profit or loss in the third quarter of 2023, and this was analyzed as a result of sales growth. HEM Pharma, which has continued to steadily increase sales over the past three years, announced that it has further solidified its foundation for stable growth with this achievement.
Since signing a 20-year exclusive contract with Global Amway in 2020, HEM Pharma has continued to steadily grow sales through healthcare commercialization services and has strengthened its presence in the domestic market through ‘My Lab’, a customized healthcare service launched in collaboration with Amway Korea. It is being strengthened further. The solid partnership between the two companies will continue in the future, and based on this, the company is achieving sales growth by expanding its healthcare services and Phytobiome product lineup.
In addition, the CDMO and biosimilar markets are expected to expand due to the promotion of biosecurity laws after the US presidential election. It is expected that supply chain diversification with friendly countries will have a positive impact on HEM Pharma along with domestic bio companies, and global expansion, including the United States, is expected to accelerate with global Amway’s preemptive investment.
Future sales growth in the customized healthcare business, advancement of key technologies including proprietary patented technology PMAS (Personalized Pharmaceutical Meta-Analysis Screening), and support for sales growth through fostering the LBP (Live Biotherapeutic Products) discovery platform business, including CDO business and technology transfer. It is expected that these results will occur.
CEO Joseph said, “Based on the current sales growth and technological innovation, we expect to easily achieve our sales goal in 2024, and we will further solidify trust in domestic and overseas markets.” In particular, he expressed his determination, “Ahead of entering the overseas market, we will continue to invest in innovative customized healthcare and technological advancement through global partnerships to establish ourselves as an industry leader that meets the expectations of customers and the market.”
Reporter Kim Jeong-hwan hwani89@segye.com
(ⓒ Segye Ilbo & Segye.com, unauthorized reproduction and redistribution prohibited)
Source: www.segye.com
